The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid
Status:
Completed
Trial end date:
2007-12-10
Target enrollment:
Participant gender:
Summary
Patients with Zollinger-Ellison Syndrome suffer from ulcers of the upper gastrointestinal
tract, higher than normal levels of gastric acid, and tumors of the pancreas known as
non-beta islet cell tumors. Patients with Zollinger-Ellison Syndrome require continuous
control of their gastric acid secretion. If gastric acid levels are permitted to rise higher
than normal, patients may develop severe ulcers and other complications.
This study will attempt to determine the effectiveness of Omeprazole (Prilosec) in the
treatment of patients with Zollinger-Ellison Syndrome. Omeprazole is a drug that functions to
decrease the amount of gastric acid secreted.
Patients for this study will be selected based on a previous diagnosis of Zollinger-Ellison
Syndrome and/or idiopathic (unknown cause) high levels of gastric acid secretion. The
patients will undergo an evaluation including history and physical examination as well as
necessary laboratory tests. The proper dose of Omeprazole will then be determined in each
patient . The proper dose of Omeprazole is considered the minimum amount of omeprazole
required to lower gastric acid to a safe level.
Every year patients participating in this study will undergo a physical examination and
history. They will be questioned about symptoms associated with Zollinger-Ellison Syndrome.
Gastric acid levels will be taken and evaluated and patients will undergo an upper
gastrointestinal endoscopy.
The effectiveness of the treatment will be measured by a clinical history to determine the
control of symptoms due to high levels of gastric acid secretion.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)